The pre-β HDL fraction constitutes a heterogeneous population of discoid nascent HDL particles. They transport from 1 to 25 % of total human plasma apo A-I. Pre-β HDL particles are generated de novo by interaction between ABCA1 transporters and monomolecular lipid-free apo A-I. Most probably, the binding of apo A-I to ABCA1 initiates the generation of the phospholipid-apo A-I complex which induces free cholesterol efflux. The lipid-poor nascent pre-β HDL particle associates with more lipids through exposure to the ABCG1 transporter and apo M. The maturation of pre-β HDL into the spherical α-HDL containing apo A-I is mediated by LCAT, which esterifies free cholesterol and thereby forms a hydrophobic core of the lipoprotein particle. LCAT is also a key factor in promoting the formation of the HDL particle containing apo A-I and apo A-II by fusion of the spherical α-HDL containing apo A-I and the nascent discoid HDL containing apo A-II. The plasma remodelling of mature HDL particles by lipid transfer proteins and hepatic lipase causes the dissociation of lipid-free/lipid-poor apo A-I, which can either interact with ABCA1 transporters and be incorporated back into pre-existing HDL particles, or eventually be catabolized in the kidney. The formation of pre-β HDL and the cycling of apo A-I between the pre-β and α-HDL particles are thought to be crucial mechanisms of reverse cholesterol transport and the expression of ABCA1 in macrophages may play a main role in the protection against atherosclerosis.
INTRODUCTION
Numerous epidemiological studies have shown that the concentration of high density lipoprotein cholesterol (HDL-C) is inversely related to coronary heart disease (Abbott et al., 1988; Wilson et al., 1988; Gotto, 2001; Gotto & Brinton, 2004) . The anti-atherogenic properties of HDLs are attributed mainly to their central role in reverse cholesterol transport (RCT), in which the HDLs accept cholesterol from cell membranes and transport it to the liver for catabolism. Additionally, the HDLs exert anti-inflammatory, anti-oxidant and anti-thrombotic actions (Gotto, 2001) . The 'gold' standard for the isolation of lipoprotein fractions is density gradient ultracentrifugation (Havel et al., 1955) . The HDLs of human plasma are conventionally defined as lipoproteins isolated in the density range of 1.063-1.21 g/ml. However, the HDL fraction constitutes a heterogeneous group of particles that may be separated into discrete subclasses on the basis of the different physicochemical properties. Indeed, ultracentrifugation distributes the HDLs into two subfractions, HDL 2 and HDL 3, of different densities, sizes and composition (Table 1) . They can be further divided into several classes of particles of different sizes by means of non-denaturing polyacrylamide gradient gel electrophoresis (Table 2) .
Ultracentrifugation should, however, be recognized as an 'invasive' method for the isolation of HDLs from plasma, which violates natural protein-particle interactions. Moreover, the ultracentrifuged HDL fraction of density of 1.063-1.21 g/ml does not contain all the HDL particles types that occur in the plasma. Oram et al. (1981) discovered that serum fraction which has a density range of 1.21-1.25 g/ml comprises apolipoprotein (apo) A-I-containing structures that are effective acceptors for cellular free cholesterol (FC). Using agarose gel electrophoresis, which is probably less disruptive than ultracentrifugation, Kunitake et al. (1985) showed the presence in the serum of a small, apo A-I-containing HDL subfraction which was characterized by pre-β mobility (pre-β HDL), unlike the majority of HDL particles migrating with α mobility (α-HDL). A slower migration in the electric field results from a weaker negative surface charge, which is related to the lack of the neutral lipid core, which also causes a flattened, discoid shape of the particles (Davidson et al., 1994) . Asztalos et al. (1993) demonstrated that the density of pre-β HDL is higher than 1.21 g/ml. Furthermore, the HDL apo E-containing particles (HDL LpE) that lack apo A-I also float at a density higher than 1.21 g/ml (Krimbou et al., 2003) .
Pre-β HDL aroused great interest when Castro and Fielding (1988) demonstrated that it is the initial acceptor of cell-derived FC. Shortly afterwards, it was shown that 60 % of cellular cholesterol efflux depends on the pre-β HDL subfraction and may involve a cell-surface protein (Kawano et al., 1993) . The discovery of the participation of pre-β HDL in the acceptance of cholesterol from cell membranes gave a new insight into HDL metabolism. This review presents selected current information on the origin and metabolism of this unique HDL subpopulation.
HETEROGENEITY OF PLASMA PRE-β HDL
Apo A-I and apo A-II are major HDL proteins (Table 1); however, only apo A-I has been detected in pre-β HDL. According to a number of studies, Apo A-I-containing serum fraction migrating with pre-β mobility represents from 1 % to 25 % of the total apo A-I in normolipidemic subjects (Kunitake et al., 1985; Castro & Fielding, 1988; Asztalos et al., 1993) . These discrepancies may reflect both biological variation and differences in the techniques used to quantify the pre-β HDL. It should be noted that the presence of lipid-free apo A-I in human plasma has been reported and that it also has a pre-β mobility when subjected to agarose gel electrophoresis (Daerr et al., 1986; Neary & Gowland, 1987) . The term 'pre-β HDL' thus includes both monomolecular lipid-free apo A-I and apo A-I-lipid complexes. Using two-dimensional agarose/non-denaturing polyacrylamide gradient gel electrophoresis, pre-β HDL may be divided into several subspecies of different particle sizes and composition (Table 3) .
The presence of a third type of pre-β HDL particles, with a molecular mass in excess of 300 kDa, has also been reported (Francone et al., 1989) . This subfraction contains only 0.2 % of total plasma apo A-I; but, unlike the others, apart from apo A-I, pre-β 3 HDL includes also lecithin : cholesterol acyltransferase (LCAT), cholesterol ester transport protein (CETP) and apo D. The first experiments on the uptake of cell-derived cholesterol from labelled cultured cells indicated a precursor-product relationship between the pre-β 1 and pre-β 2 HDL subclasses (Castro & Fielding, 1988) . The composition of pre-β 3 HDL suggests participation in esterification and transfer of cholesterol (Francone et al., 1989) ; however, the detailed function of pre-β 3 has not been recognized yet.
PREDICTED STRUCTURE OF PRE-β HDL PARTICLE
Apo A-I is the only protein detected in pre-β 1 and pre-β 2 HDL and is considered a key factor in modulating both the structure and function of pre-β HDL. The apo A-I molecule is a 243-amino-acid (28 kDa) polypeptide. It belongs to the exchangeable apolipoproteins that are capable of moving from one lipoprotein particle to another. Pivotal roles in the structure of these apolipoproteins are played by amphipathic α helices, with clearly distinguished polar and hydrophobic faces (Segrest et al., 1992; Frank & Marcel, 2000) . The molecule of apo A-I contains the N-terminal globular region (residues 1-43) and eight 22-and two 11-mer repeats that are usually separated by proline residues (Davidson & Thompson, 2007) . Isolated apo A-I combines spontaneously with phospholipids (PL) to form complexes of different PL/ apo A-I ratios which are known as reconstituted HDL (rHDL) and resemble pre-β HDL (Atkinson & Small, 1986; Jonas et al., 1989; Brouillette & Anantharamaiah, 1995) . Lipid binding is predicted to be mediated by the C-terminus of apo A-I, while the N-terminal and central regions are primarily responsible for structural integrity (Saito et al., 2004) . In the lipid-free state, the N-terminal domain forms a helix bundle, whereas the C-terminal domain is less organized (Saito et al., 2003) . Lipidation of apo A-I is accompanied by a transition from a compact to an extended structure of stable conformation, with an increase in the α helical content from 40-50% to 70-80% (Jonas et al., 1989; 1990; Saito et al., 2003) .
It is widely believed that the pre-β 1 HDL particle in the plasma contains two copies of apo A-I (Barrans et al., 1996; Rye & Barter, 2004; Wu et al., 2007) . However, the study conducted by Chau et al. (2006) shows that the pre-β 1 particle may contain only one molecule of apo A-I. The pre-β 1 particles containing one or two molecules of apo A-I may represent successive stages of nascent HDL generation (Chau et al., 2006; Duong et al., 2008) .
Experiments with rHDL led to two basic models of discoid HDL particles, composed of two molecules of apo A-I and about 160 PL molecules. The first was the 'picket fence model' in which the amphipathic α-helices of each apo A-I molecule, separated by reverse turns at the proline residues, were arrayed around the periphery of the lipid core in an anti-parallel fashion (Nolte & Atkinson, 1992; Phillips et al., 1997) . The picket fence model took into account the presence in the central region of apo A-I of a hinge domain loosely associated with lipids and responding to changes in the lipoprotein particle diameter by folding or unfolding (Frank & Marcel, 2000; Davidson & Silva, 2005) .
Current data support the alternative 'double-belt' model ( Fig. 1 ) in which two anti-parallel apo A-I molecules, adopting an extended helical structure, wrap around the edge of the disc (Segrest et al., 1999; Davidson & Thompson, 2007; Wu et al., 2007) . Presumably the stabilization of the lipid-bound conformation is ensured by salt bridges between the two adjacent apo A-I molecules. The conformational adaptability of apo A-I in relation to the changing lipid content is consistent with the recently presented 'looped-belt' or 'solar flares' model of discoid HDL particles (Martin et al., 2006; Wu et al., 2007; Thomas et al., 2008) . In this model, the central apo A-I regions are more solventexposed and protrude from the edge of the disc. These loops could be LCAT interaction sites and are crucial for LCAT activation (Wu et al., 2007) .
THE ABCA1 TRANSPORTER IS A KEY PROTEIN IN PRE-β HDL BIOGENESIS
Tangier disease is a rare genetic disorder which was described in the early 1960s (Fredrickson, 1964) . It is characterized by a lack of the plasma HDL fraction, extremely low concentrations of apo A-I, and accumulation of cholesteryl esters (CE) in macrophages. It was suggested that the clinical and biochemical features of Tangier disease result from a defective efflux of cholesterol and phospholipids (Francis et al., 1995) . In 1999, the association between Tangier disease and genetic defects in the ATP-binding cassette transporter A1 (ABCA1) gene was discovered by teams led by Michael Hayden, Gerd Schmitz and Gerd Assmann (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Rust et al., 1999) . ABCA1 is a member of a superfamily of 49 mammalian ATP-binding cassette transporters that transport metabolites across membranes at the expense of ATP hydrolysis (Kielar et al., 2001; Oram & Heinecke, 2005) . ABCA1 is expressed in the liver, macrophages, brain and other tissues (Kielar et al., 2001) . It localizes to intracellular compartments and the plasma membrane (Oram & Heinecke, 2005) . ABCA1 promotes the transport of PL and FC to lipid-free apo A-I and other exchangeable apolipoproteins (apo A-II, apo E, apo CI, apo CII, apo CIII, apo A-IV) containing amphipathic α-helices (Fitzgerald et al., 2004; Oram & Heinecke, 2005) . The interaction between ABCA1 and apo A-I leads to the lipidation of apo A-I and generation of the discoid nascent pre-β 1 HDL particle (Vedhachalam et al., 2007a) . In Tangier disease patients the lack of functional ABCA1 transporters halts the PL and FC efflux, which results in the accumulation of CE in the cells and rapid degradation of apo A-I in the kidney . Experiments on sophisticated animal models bearing target-inactivating mutations of ABCA1 gene in specific tissues have proved that it is predominantly the liver and, to a lesser extent, the intestine which contribute to the biogenesis of circulating HDL particles (approximately 70 % and 30 %, respectively) Timmins et al., 2005; Brunham et al., 2006) . There is a widespread belief that, although the expression of ABCA1 in macrophages does not influence the HDL concentration significantly, it may be a key mechanism in preventing the development of atherosclerosis (Cuchel & Rader, 2006; Attie, 2007) . Recently, a positive relationship has been demonstrated between the ABCA1-dependent macrophage cholesterol efflux and the concentration of pre-β 1 HDL in the serum of healthy human subjects (de la LleraMoya et al., 2010) .
However, worthy of note is that a fraction of apo A-I may be lipidated in non-ABCA1-dependent process. This thesis is consistent with a study presented by Kiss et al. (2003) , who demonstrated that ABCA1 deficiency does not completely block the lipidation of apo A-I in primary mouse hepatocytes, expressing human apo A-I (hapo A-I) or incubated with exogenously added hapo A-I.
The primary substrate for ABCA1 is lipid-free monomolecular apo A-I. The C-terminal domains of apo A-I, which are characterized by the greatest affinity for lipids, seem to play a crucial role in the interaction between apo A-I and ABCA1 (Favari et al., 2002; Liu et al., 2003; Hassan et al., 2007) . Studies with synthetic peptides which mimic apolipoproteins have indicated that the interaction between apo A-I and ABCA1 is not sequence-specific; instead, amphipathic helices of apo A-I were found to be the key structural motif (Remaley et al., 2003 ; Gonzal- Fraction of total apo A-I in healthy subjects [%] 4.6-6.3 0.9-4.3 (Asztalos et al., 1993; O'Connor et al., 1998; Xu & Fu, 2003) Molecular mass [kDa] 65-80 325 (Ishida et al., 1987; Castro & Fielding, 1988; Barrans et al., 1996; O'Connor et al., 1998; Chau et al., 2006) Apo ez et al., 2008) . Apo A-I directly interacts with residues located in two extracellular loops of ABCA1 (Fitzgerald et al., 2002) .
A number of observations imply that ABCA1 targets specific cholesterol-rich membrane domains (Oram et al., 2000; Mendez et al., 2001; Wang et al., 2001; Hassan et al., 2007; Vedhachalam et al., 2007b) . The properties of these domains remain unclear. Caveolae are among the likely plasma membrane domains where ABCA1-mediated cholesterol efflux takes place. Caveolae are freecholesterol-rich invaginated microdomains at the surface of most peripheral cells . The main structural component of caveolae -caveolin-1 -binds free cholesterol. In aortic endothelial cells, ABCA1 interacts directly with both caveolin-1 and apo A-I and may act as a structural platform between caveolin-1 and HDL (Chao et al., 2005) .
On the other hand, there is some evidence that lipid rafts which lack structural protein components may also be involved in cholesterol efflux from macrophages (Gaus et al., 2004) . However, they are thought not to be a source of lipid for apo A-I, serving instead as a functional platform enabling stimulation of ABCA1-dependent cholesterol efflux. A recently presented biophysical study confirms that ABCA1 destabilizes raft domains and redistributes FC to cell surface domains readily accessible to apolipoproteins (Zarubica et al., 2009) . Finally, it is also possible that ABCA1 associates with membrane domains distinct from both caveolae and lipid rafts (Mendez et al., 2001; Liu et al., 2003) .
PUTATIVE MECHANISM OF EXTRACELLULAR PRE-β HDL FORMATION
The minimal functional unit required for the biogenesis of HDL particles is thought to be the homotetrameric ABCA1 complex (Denis et al., 2004a) . The molecular mechanism of ABCA1-mediated lipid efflux to apo A-I is not fully understood. Chau et al. (2006) demonstrated that human liver or colon-derived cells secrete apo A-I in a globular form with a Stokes diameter of 5.2 nm that binds neither PL nor FC and migrates in agarose gel with a pre-α mobility. This inactive in binding lipids form is converted by ABCA1 transporter into a product with a diameter of 7.2 nm, which probably results from the refolding of the spherical apo A-I particle into a tubular form. This process is ABCA1-dependent but is not accompanied by PL transfer. Lipids are subsequently transferred to the refolded apo A-I, resulting in the generation of the biologically active pre-β 1 lipid-poor particle (Fig. 2) . Chau et al. (2006) hypothesized that the inability to bind lipids by the newly produced apo A-I may promote the distribution of lipid-free apo A-I to the extracellular space of peripheral tissues.
An important issue is whether the ABCA1-mediated transport of FC and PL to lipid-poor apo A-I is simultaneous or sequential. The 'microsolubilization' model presented by Gillotte et al. (1998) assumed that pre-β 1 particles result from a simultaneous transfer of FC and PL to lipid-free apo A-I. However, experimental evidence supports the idea that ABCA1 does not bind cholesterol directly, but acts primarily as a PL translocase. Nowadays, therefore, a two-stage transfer model of pre-β HDL generation is taken into consideration, according to which the binding of apo AI to ABCA1 would lead first to the generation of a PL-apo A-I complex that would subsequently promote FC efflux Wang et al., 2001) . The separation of PL and cholesterol efflux has recently been confirmed by studies carried out on humans with severe HDL deficiency (Rashid et al., 2009) .
Cells expressing ABCA1 secrete heterogeneous nascent pre-β HDL subpopulations (Mulya et al., 2007; Duong et al., 2008) . This diversity may be related to the multi-stage process of nascent HDL formation. In vitro, the binding of small amounts of PL and cholesterol to apo A-I results in the formation of rHDL containing one apo A-I molecule while the incorporation of a greater number of PL molecules promotes the generation of a particle with two apo A-I molecules (Sparks et al., 1999) . Duong et al. (2008) have shown that primary pre-β 1 particles with the diameter of 7.5 nm generated during the interaction between apo A-I and ABCA1, contained three or four PL molecules and one molecule of apo A-I. These lipid-poor complexes were subsequently converted into discs containing 100-200 PL molecules and two, three or four apo A-I molecules. Thus, the small nascent particles could serve as precursors of a larger nascent HDL. This leads us to the conclusion that pre-β 1 is both a product and a substrate for ABCA1-mediated lipid efflux and raises the question as to whether there exists a limit of apo A-I lipidation that inactivates the interaction between ABCA1 and apo A-I. Mulya et al. (2007) demonstrated that even a minimal association of PL with apo A-I (5-9 molecules of PL per one molecule of apo A-I) significantly reduces its binding to ABCA1. On the other hand, experiments with rHDL composed of apo A-I and polmitoyl-oleoyl phosphatidylcholine (POPC) proved that up to 82 PL molecules can bind to apo A-I without abolishing its functionality as a ligand for ABCA1 (Favari et al., 2009) . This indicates that a conformational rearrangement of the apo A-I molecule, rather than lipidation, may be a key factor preventing lipid-poor pre-β 1 from interacting with ABCA1.
The multi-stage model of HDL biogenesis is consistent with experiments demonstrating that ABCA1 activity creates two types of apo A-I-binding sites on the cell surface (Hassan et al., 2007; Vedhachalam et al., 2007b) . The first site is formed by a direct interaction between apo A-I and ABCA1. It is characterized by low specificity, most probably because it occurs between the amphipathic α-helices of apo A-I and hydrophobic regions of the largest ABCA1 extracellular loop. The low capacity site binds about 10 % of the apo A-I which is present on the surface of cells (Vedhachalam et al., 2007b) . The binding with apo A-I protects ABCA1 from proteolytic degradation Wang et al., 2003) and independently activates Janus kinase 2 (Tang et al., 2006) . Thus, the low capacity site may have a regulatory function. The second, high capacity site is a membrane lipid site. The high affinity results from the penetration of the space between the PL polar groups in the highly curved membrane bilayer by the amphipathic α-helices of apo A-I.
A three-step model of the interaction between ABCA1 and apo A-I proposed by Vedhachalam et al. (2007a) explains the contribution of the interaction of apo A-I with ABCA1 and membrane lipids, as well as the heterogeneous nature of the nascent HDL particles (Fig. 3) .
Step 1 involves direct binding of a small number of apo A-I molecules to a specific ABCA1 site. The binding of apo A-I by ABCA1 would induce signalling responses that would stabilize ABCA1 and enhance PL translocase activity. This would lead to the compression of the PL molecules in the exofacial leaflet of the membrane, which would bulge in the direction of the extracellular space. In step 2, more apo A-I would bind to the membrane protrusions.
Step 3 would involve membrane microsolubilization and the creation of discoid nascent HDL particles. This stage would limit the rate of the entire ABCA1 -apo A-I interaction. The variations in the lipid composition of membrane curvatures created in different membrane environments would cause the heterogeneity of nascent HDLs, particularly in terms of FC content.
It is also likely that ABCA1-dependent lipidation of apo A-I occurs by retroendocytosis (Neufeld et al., 2004; Azuma et al., 2009 ). This concept is consistent with the traffic of early endosomes containing ABCA1 between the plasma membrane and other endocytic compartments (Takahashi & Smith, 1999; Neufeld et al., 2001; Oram & Heinecke, 2005) . According to this hypothesis, the interaction between ABCA1 and apo A-I would be followed by endocytosis of vesicles containing ABCA1 and apo A-I to intracellular lipid deposits. There, ABCA1 would pump the lipids to the vesicle lumen for release by exocytosis.
INTRACELLULAR ASSEMBLY OF HDL PARTICLES
Apo A-I is synthesized in the liver and intestine (approximately 80 % and 20 %, respectively) (Wu & Windmueller, 1979; Timmins et al., 2005) . In the past, HDL was thought to be formed through an intracellular assembly of discoid particles in the Golgi (Hamilton et al., 1976; Banerjee & Redman, 1983; McCall et al., 1988) . Nowadays, there is no doubt that the extracellular lipidation of newly secreted lipid-free apo A-I through interaction with ABCA1 is an important source of pre-β HDL (Chau et al., 2006) . However, from 20 % to 50 % of newly synthesized apo A-I may be lipidated intracellularly prior to secretion (Chisholm et al., 2002; Maric et al., 2005) . A study by Maric et al. (2005) showed that the initial phospholipidation of apo A-I in primary mouse hepatocytes occurred in the endoplasmic reticulum (ER), probably immediately after translation, and did not depend on ABCA1. It was postulated that the affinity of newly synthesized apo A-I to PL is related to proper protein folding. Apo A-I would then transit from ER to the Golgi where it would interact with ABCA1 and bind more PL. Finally, the apo A-I would leave the Golgi and accumulate in the media.
ABCG1 AND APO M -NEW FACTORS INVOLVED IN PRE-β HDL FORMATION
While ABCA1 mediates lipids efflux to free/lipid-poor apo A-I, subsequent lipidation of nascent lipid-poor pre-β HDL most probably occurs in a non-ABCA1-mediated process. A partner of ABCA1 in the removal of cholesterol from cells was recently identified as the ABCG1 transporter (Gelissen et al., 2006; Favari et al., 2009) . ABCG1 is widely expressed in macrophages, adipocytes, lung, brain and other tissues. Although the ABCG1 proteins are predominantly intracellular, associated with the endoplasmic reticulum and Golgi membranes, their movement to the plasma membrane of macrophages has also been demonstrated (Klucken et al., 2000; Vaughan & Oram, 2005) . Little is known about the mechanism of the ABCG1-mediated transport of FC. It may proceed by aqueous diffusion, since the cholesterol acceptor does not necessarily bind to a donor cell (Wang et al., 2004; Sankaranarayanan et al., 2009) . The role of ABCG1 could be the redistribution of cholesterol to a cell surface pool that is accessible for enzymatic oxidation and removal by HDL.
The most important feature of ABCG1 is probably its ability to promote lipidation not only of nascent pre-β 1 HDL, but also of mature HDL particles (Wang et al., 2004; Vaughan & Oram, 2005; Sankaranarayanan et al., 2009 ) that constitute the majority of circulating HDLs. Disruption of the ABCG1 gene in mice causes massive accumulation of neutral lipids in macrophages and the liver, whereas overexpression of ABCG1 prevents it (Kennedy et al., 2005) . Thus, the ABCG1 transporter may also be involved in tissue lipid homeostasis. ABCG1 proteins may have a significant share in mediating cholesterol efflux from macrophage foam cells and thus play an important role in preventing against atherosclerosis (Wang et al., 2004) . Step 1: binding of a small amount of apo A-I to ABCA1 increases ABCA1 activity. Membrane PL actively translocate from the cytoplasmic to the exofacial leaflet of the membrane. The accumulation of lipid molecules in the exofacial leaflet and the net depletion of PL molecules in the cytoplasmic leaflet induce strain in the membrane.
Step 2: highly curved exovesiculated domain relieves the membrane strain. Apo A-I molecules bind with high affinity to the PL bilayer curvature.
Step 3: discoidal HDL particles are formed as a result of spontaneous solubilization of membrane PL and cholesterol by apo A-I. After: Vedhachalam et al., 2007a . PL, phospholipids; ABCA1, ATP-binding cassette transporter A1.
Apo M was discovered in 1999 (Xu & Dahlback, 1999) and soon emerged as a new player in of pre-β HDL formation and also thereby in RCT (Hu et al., 2010) . Human apo M is an about 25 kDa protein that belongs to the lipocalin superfamily (Luo et al., 2004 , Nielsen et al., 2009 . Thus, it is thought to possess a hydrophobic pocket binding lipophilic molecules. Apo M is highly expressed in the kidney and liver. Kidney-derived apo M is probably catabolized in proximal tubules, while apo M synthesized in hepatocytes is secreted to the blood, where it associates predominantly with HDL particles (Nielsen et al., 2009) . The binding of apo M to HDL has a unique nature, because this protein is anchored there by its retained signal peptide. However, it should be stressed that apo M is a component of only 5 % of the HDLs in the plasma. The mean plasma concentration of apo M is about 23 mg/L (Nielsen et al., 2009) . In mice, a lack of apo M led to the disappearance of pre-β HDL in the plasma and a significant decrease of HDL-C (Wolfrum et al., 2005) . This suggests that apo M is critical for pre-β HDL formation in vivo. In turn, overexpression of the apo M gene caused a two-fold increase of HDL-C concentration in the plasma and a reduction of atherosclerotic lesions. Using human kidneyderived cells, Mulya et al. (2010) recently proved that apo M expression is not necessary for the generation of nascent HDL by ABCA1, but it promotes the formation of larger nascent HDL particles. This may result from both the transfer of lipids from smaller to larger particles and from the fusion of small pre-β 1 particles. It is also likely that apo M-mediated lipidation of pre-β HDL particles occurs at an intracellular site.
ROLE OF LCAT IN PRE-β HDL MATURATION
Discoid HDL is an intermediate between lipid-free apo A-I and the mature, spherical HDL. The critical step in the transformation of a nascent to a mature form of HDL is the esterification of cholesterol catalyzed by LCAT. It is a 416-amino-acid glycoprotein produced mainly by the liver and circulating in the blood reversibly bound to lipoproteins, preferentially to HDL (Jonas, 2000) . LCAT transfers a long-chain fatty acid residue from the sn-2 position of phosphatidylcholine to the 3-β-hydroxyl group of cholesterol to produce a cholesteryl ester and lysolecithin. LCAT is active on the surface of both HDL (α activity) and LDL (β activity) (Kuivenhoven et al., 1997) . Apo A-I is the major activator of LCAT on HDL (Fielding et al., 1972; Jonas, 1986; . The importance of LCAT for HDL maturation is demonstrated by rare total (familial LCAT deficiency) or partial (fish eye disease) deficiency states, which are related to a markedly decreased plasma HDL-C and the accumulation in the plasma of nascent discoid HDL particles forming aggregates (McIntyre, 1988; Asztalos et al., 2007) . In vitro experiments with both rHDL and native lipoproteins indicated that lipid-poor pre-β particles are direct and preferential substrates for LCAT (Jonas et al., 1990; Kosek et al., 1999; Nakamura et al., 2004; Shih et al., 2009) . Jonas et al. (1990) demonstrated that LCAT preferred as its substrate discoid rHDL 34-fold over spherical rHDL with a similar particle size. Thus, the rate of cholesterol esterification is the highest in lipidpoor apo A-I followed by discoid HDL and spherical HDL (Jonas, 1986; Neary et al., 1991; Sparks et al., 1999; Nakamura et al., 2004) .
It was presumed that the movement of CE to the centre of the disc forms a hydrophobic core and transforms the flattened structure into a sphere (Jonas, 1986) . Recent molecular dynamics simulations have confirmed that the discoid HDL spontaneously forms a spherical particle through the gradual incorporation of CE (Shih et al., 2009) . The absorption of CE increases the solventaccessible surface area of PL, which enables the recruitment of additional apo A-I molecules (Shih et al., 2009 ). This conclusion is consistent with previous studies which demonstrated that LCAT mediates the incorporation of lipid-free apo A-I into rHDL (Liang et al., 1996) .
FORMATION OF HDL CONTAINING BOTH APO A-I AND APO A-II (HDL A-I/A-II)
About half of mature HDLs contain also apo A-II. Apo A-II is a homodimer of two 77-amino acid polypeptides linked by a disulfide bond at residue 6 (Blanco-Vaca et al., 2001) . Like apo A-I, apo A-II associates spontaneously with phospholipids, forming discoid structures (rHDL A-II) (Atkinson & Small, 1986) , and accepts PL and FC from cell membranes, producing discoid nascent HDL-like lipoproteins (Hara & Yokoyama, 1991) . In contrast to apo A-I, little is known about the structure of apo A-II in rHDL. Data presented by Silva et al. (2007) support the presence of a belt-like structure of apo A-II in POPC rHDL particles.
Apo A-II is mainly produced by the liver (Wu & Windmueller, 1979) . This apolipoprotein is lipidated intracellularly and secreted as discoid pre-β-migrating nascent HDL A-II (Gillard et al., 2009) . To date, pre-β HDL A-II particles have not been detected in the serum from healthy humans, but have been reported in serum from LCAT-deficient subjects (Rader et al., 1994; Asztalos et al., 2007) and in transgenic mice overexpressing human apo A-II (Fournier et al., 2002) . From 5 % to 25 % of serum apo A-II is associated with PLrich, spherical particles that do not contain apo A-I (HDL A-II) (Bekaert et al., 1992) , which suggests the possibility of a transformation of nascent pre-β HDL A-II into the mature form by unknown mechanisms. A small fraction of apo A-II is associated with very low density lipoproteins (VLDL) and chylomicrons; however, most apo A-II in human serum is found in HDL A-I/A-II particles (Blanco-Vaca et al., 2001) . The lack of discoid HDL A-II in serum suggests rapid formation of HDL A-I/A-II. Indeed, experiments with rabbits that are naturally deficient in apo A-II have confirmed the very rapid incorporation of both lipid-free apo A-II and rHDL A-II entering the plasma to spherical HDL particles (Hime et al., 2006) . The mechanism mediating the formation of HDL A-I/A-II is unclear. The central role in this process seems to be played by LCAT. It does not convert discoid HDL A-II into spherical forms (Forte et al., 1995) ; however, it is thought to mediate the fusion of nascent discoid HDL A-II with spherical HDL A-I to form spherical HDL A-I/A-II (Clay et al., 2000; Gillard et al., 2009) . Another possible mechanism for the generation of HDL A-I/A-II is based on the ability of apo A-II to displace apo A-I from HDL particles, which is caused by the higher affinity of apo A-II to lipids (van Tornout et al., 1981) . The impact of apo A-II on the HDL structure is not clear. The presence of apo A-II may enhance HDL stability (Rye et al., 2003; Boucher et al., 2004) .
GENERATION OF PRE-β HDL FROM MATURE PLASMA HDLS
Soon after the participation of pre-β HDL in RCT had been discovered, Kunitake et al. (1992) postulated that apo A-I cycles between pre-β HDL and α-HDL in response to the movement of CE through the HDL compartment. Indeed, a fraction of apo A-I may dissociate from HDLs during their plasma remodelling mediated by a number of factors, such as CETP, phospholipid transfer protein (PLTP) and hepatic lipase (HL). Kinetic analysis demonstrated that the generation of pre-β 1 HDL from α-HDL was approximately 10 times slower than the conversion of liver-derived pre-β 1 to α-HDL (Chetiveaux et al., 2004) .
CETP and PLTP are lipid-transfer proteins that play a central role in the regulation of HDL level in the blood. CETP is a hydrophobic plasma glycoprotein composed of 476-amino acids with four N-linked glycosylation sites. It is expressed in the liver, small intestine, adipose tissue, spleen and macrophages (Masson et al., 2009) . CETP promotes the transfer of CE from HDL to apo B-containing lipoproteins (VLDL and low density lipoproteins, LDL) in exchange for triacylglycerols (TG) (Masson et al., 2009) . Thus CETP action depletes the HDL core of CE and enriches it with TG. A genetic deficiency of CETP is related to markedly increased HDL-C concentrations and altered HDL particle distribution -the proportion of larger particles is increased and of small pre-β 1 particles -decreased (Hirano et al., 1997; Arai et al., 2000; Asztalos et al., 2004) . In mice, which normally lack CETP (Masson et al., 2009) , the expression of human CETP leads to increased pre-β HDL levels (Francone et al., 1996) . It has been shown that during in vitro HDL remodelling by CETP, up to 36 % of apo A-I may be released from HDL in a lipid-free or lipidpoor form (Liang et al., 1994) . Experiments with spherical rHDL also suggest that CETP may promote fusion of the HDLs (Rye et al., 1997) .
PLTP is a 476-amino acid protein with six N-linked glycosylation sites which shuttles the PL derived from lipolyzed TG-rich lipoproteins (chylomicrons and VLDL) to HDLs (Tall et al., 1985; Masson et al., 2009) . PLTP is widely expressed in the organs (Masson et al., 2009) . The importance of PLTP to the maintenance of HDL levels is proved by a markedly reduced HDL-C level in mice lacking PLTP (Jiang et al., 1999) . Epidemiological studies confirm the relationship between variants of the PLTP gene and the regulation of HDL-C in humans (Aouizerat et al., 2006) . In vitro, PLTP changes human HDL 2 and HDL 3 particle distribution by converting the particles into both larger and smaller subpopulations (Jauhiainen et al., 1993; Marques-Vidal et al., 1997) . These changes are accompanied by a loss of apo A-I and the generation of pre-β 1 HDL particles (von Eckardstein et al., 1996; Marques-Vidal et al., 1997) . On the basis of experiments carried out with rHDL, Lusa et al. (1996) postulated that the interaction of PLTP with HDL at first induces the release of apo A-I from the HDL. This destabilizes the HDL particles, which subsequently undergo fusion into larger, thermodynamically stable particles.
Hepatic lipase is a lipolytic enzyme with a broad substrate specificity, which hydrolyzed PL and TG in HDLs (Thuren, 2000) . Epidemiological studies indicate that HL gene polymorphism strongly influences HDL-C levels (Guerra et al., 1997; Murtomaki et al., 1997; Andersen et al., 2003; Hodoglugil et al., 2010) . The lipolysis mediated by HL reduces the size of the HDL particles and generates small amounts of pre-β 1 HDL particles (Clay et al., 1991; Barrans et al., 1994) . The enrichment of HDL with TG significantly enhances the loss of apo A-I from HDL and pre-β 1 production by HL (Hopkins & Barter, 1986; Clay et al., 1991; Barrans et al., 1994) . Clay et al. (1992) demonstrated that the combined action of HL and CETP causes the loss of up to 30 % of apo A-I from HDLs.
Several metabolic transformations of the lipid-free/ lipid-poor apo A-I shed from HDLs during their plasma remodelling are possible. These are: incorporation into pre-existing HDL particles (Liang et al., 1995) , fusion with newly secreted discoid HDL A-II and the formation of new generations of HDL A-I/A-II particles (Rye & Barter, 2004) , yielding new pre-β HDL particles by incorporation of lipids from other lipoproteins (Clay et al., 1992; Clay & Barter, 1996) , and mediation of cellular cholesterol efflux in an ABCA1-dependent manner (Okuhira et al., 2004) . However, lipid-poor apo A-I can also be catabolised in the kidney and irreversibly lost (Horowitz et al., 1993; Lamarche et al., 1999) .
It is not known whether the remodelling of mature HDLA-I/A-II in the plasma generates lipid-poor apo A-II. An experiment with rHDL demonstrated a substantial difference between apo A-I and apo A-II in respect to their ability to be transferred into the aqueous phase (Pownall et al., 2007; Gao et al., 2009) . On the other hand, studies on HDL remodelling mediated by PL have demonstrated the formation of new apo A-II-containing particles resembling nascent HDL (Tall & Green, 1981; Wróblewska et al., 2009; . Experiments in vitro proved that both pre-β HDL A-II and purified apo A-II stimulate cholesterol efflux in an ABCA1-dependent manner (Fournier et al., 2002; Fitzgerald et al., 2004) . The recently published results of the European Prospective Investigation into Cancer and Nutrition -Norfolk study showed an inverse correlation between serum apo A-II levels and the risk of future coronary artery disease in apparently healthy subjects (Birjmohun et al., 2007) . The possible involvement of apo A-II in RCT remains to be established.
NASCENT HDL PARTICLES MAY EXHIBIT α-ELECTROPHORETIC MOBILITY
Nascent apo A-I-containing particles of pre-β mobility are thought to be the major source of HDL in the plasma. However, it should be remembered that pre-β mobility is only a physical feature and results from the surface electric charge of lipoprotein particles. The AB-CA1-dependent formation of nascent HDL A-I particles migrating with α mobility has also been demonstrated (Denis et al., 2004b; Krimbou et al., 2005) . These particles also interacted efficiently with LCAT (Krimbou et al., 2005) . The α-electrophoretic mobility may have been due to the high content of phosphatidylinositol or to the high number of apo A-I molecules per particle (Denis et al., 2004b ). An analysis of nascent apo A-I-containing HDL generated by the incubation of exogenously added lipid-free apo A-I with various cell lines suggested that speciation of nascent HDL into pre-β and/or α-HDL is linked to specific cell lines (Krimbou et al., 2005) . So far, little is known about the metabolism of nascent α-HDL and whether its physiological role differs from that of pre-β HDL.
CONCLUDING REMARKS
Reverse cholesterol transport allows the maintenance of cholesterol homeostasis in the body and affords protection against atherosclerosis. The first step of RCT is the efflux of FC from the cell membrane. This occurs as a result of the interaction between lipid-free apo A-I and ABCA1 protein and generates discoid pre-β HDL particles capable of taking up FC from cell membranes. The remodelling of mature HDLs in the plasma, mediated by lipid transfer proteins and hepatic lipase, is also the source of pre-β HDL particles. Research on pre-β HDL has opened up new possibilities for atheroprotective therapies augmenting the RCT. These include such strategies as the use of synthetic pre-β HDL prepared from recombined apo A-I, or small apo A-I mimetic peptides combined with phospholipids (Shah, 2007) and the elevation of de novo apo A-I synthesis and, thereby, of HDL formation (Dullens et al., 2007) .
